Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RetinalGenix Technologies's enterprise value is $75.43 Mil.
RetinalGenix Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.43 Mil. Therefore, RetinalGenix Technologies's EV-to-EBITDA for today is -31.10.
The historical rank and industry rank for RetinalGenix Technologies's EV-to-EBITDA or its related term are showing as below:
RTGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.1 Med: 0 Max: 0
Current: -31.1
RTGN's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 14.89
vs RTGN: -31.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RetinalGenix Technologies's PE Ratio (TTM) for today is calculated as:
RetinalGenix Technologies's share price for today is $4.00.
RetinalGenix Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.124.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RetinalGenix Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RetinalGenix Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RetinalGenix Technologies's EV-to-EBITDA falls into.
RetinalGenix Technologies's current Enterprise Value is $75.43 Mil.
RetinalGenix Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RetinalGenix Technologies (RTGN) has a EV-to-EBITDA of -31.10 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RetinalGenix Technologies.
Is RetinalGenix Technologies' EV-to-EBITDA too high?
RetinalGenix Technologies' current EV-to-EBITDA is -31.10. Overall, RetinalGenix Technologies has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does RetinalGenix Technologies' EV-to-EBITDA compare to SNWV and NNOX?
RetinalGenix Technologies' EV-to-EBITDA of -31.10 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBITDA is 14.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.89, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RetinalGenix Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RetinalGenix Technologies's current EV-to-EBITDA is -31.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RetinalGenix Technologies stock overvalued right now?
RetinalGenix Technologies (RTGN) has a current EV-to-EBITDA of -31.10. The current EV-to-EBITDA is -31.10. RetinalGenix Technologies' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For RetinalGenix Technologies (RTGN), the current EV-to-EBITDA is -31.10 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: Retinal Imaging Screening Device a portable, retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available.
30GF Score
Get the complete analysis for RTGN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RTGN has been successfully added to your 
